Aptose Biosciences Inc.

Toronto Stock Exchange:APS.TO

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

Canada

Market Cap

USD 2.03 M

Share Price

USD 0.80

Avg Daily Volume

4,966

Change (1 day)

-3.80%

Change (1 year)

Change (YTD)

308.02%

Aptose Biosciences Inc. Revenue for the year ending December 31, 2024

Aptose Biosciences Inc. Revenue is NA for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Aptose Biosciences Inc. Revenue for the year ending December 31, 2023 was USD 0.00.
Aptose Biosciences Inc. Revenue for the year ending December 31, 2022 was USD 0.00.
Aptose Biosciences Inc. Revenue for the year ending December 31, 2021 was USD 0.00.
Aptose Biosciences Inc. Revenue for the year ending December 31, 2020 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Toronto Stock Exchange: APS.TO

Aptose Biosciences Inc.

CEO	Dr. William G. Rice Ph.D.
IPO Date	April 25, 1996
Location	Canada
Headquarters	251 Consumers Road
Employees	13
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.